Anne
Fulenwider

Anne Fulenwider runs a healthcare company the way she once ran a masthead: by deciding what gets attention and what gets ignored. Her company, Alloy Women's Health, exists to give attention to a subject medicine has spent generations looking past - perimenopause and menopause. She is its co-founder and one of two co-CEOs, sharing the chair with Monica Molenaar, and she came to the job from the least clinical background imaginable.

Alloy is a fully digital practice. It connects women to board-certified, menopause-trained physicians, builds a customized treatment plan, and ships doctor-prescribed medication to the door, with asynchronous messaging so a question at 2 a.m. doesn't have to wait for an appointment that's three weeks out. Since launching, it has grown to roughly 71 employees and raised about $21 million, including a Series A reported in late 2024. That's the operating reality. The more interesting part is how a woman who never took a science class she didn't have to ended up running it.

Fulenwider's entire prior life was words. She graduated from Harvard in 1995 with a degree in English and American Literature, magna cum laude, and walked straight into journalism through an internship at David Lauren's startup magazine, Swing. Her real apprenticeship came next, as an assistant to George Plimpton at The Paris Review, where she helped research his biography of Truman Capote. Working for Plimpton is the kind of credential you can't engineer - it just happens to people who show up early and pay attention. She paid attention.

From there came a decade at Vanity Fair as a senior editor, where she handled writers most editors only read: Dominick Dunne, Buzz Bissinger, Fran Lebowitz. Editing Lebowitz is its own form of hazard pay. By 2009 she had moved to Marie Claire as executive editor under Joanna Coles, detoured briefly to run Brides in 2011, and in 2012 took the top job at Marie Claire. She held it for eight years.

Under Fulenwider, Marie Claire stopped being only a fashion book. She launched the Image Makers Awards to honor the stylists and artists behind Hollywood, created Fresh Faces to spotlight rising talent, and built The Power Trip, a bicoastal conference that put powerful women in the same room and won Hearst's Innovation of the Year in 2017. She ran the magazine's first sustainability issue. The industry noticed: Editor of the Year honors in 2013 and 2015, a Women in Media leadership nod in 2016. She also judged Project Runway and mentored on its All Stars edition, because the editor's job, then as now, was deciding who deserved the spotlight.

Then in 2016 her mother died of a sudden heart attack. Grief reorganizes priorities, and hers reorganized around a question that wouldn't leave: why is so much of women's health, especially the second half of it, treated as something to endure quietly? She had spent a career telling women how to live. She started wondering whether she could help them live better. In late 2019 The New York Times reported she was leaving Marie Claire to build a startup in women's health. She co-founded Alloy in 2020 with Molenaar, and the two have run it as equals ever since.

What she brought to healthcare wasn't a medical degree. It was an editor's instinct for narrative and an editor's allergy to jargon. Menopause has a marketing problem and an information problem, and both are storytelling problems. Fulenwider's bet is that the same skill that turned a fashion magazine into a platform for women's ambition can turn an overlooked stage of life into a category people talk about out loud. In 2024 Forbes named her to its 50 Over 50 list, a tidy endorsement of her own favorite line: success and innovation have no age limit.

She is candid that she had no business knowing how to do any of this, and that the not-knowing was the point. "One thing that's really undersold," she has said, "is some naivete and the ability to close your eyes, jump, and have confidence that when you land, you will figure it out." It is the rare founder quote that doubles as an accurate job description. She closed her eyes at the height of a media career and jumped into a field she'd never worked in. She is still figuring it out, in public, at scale, which is more or less what she signed up for.

The co-CEO arrangement is worth dwelling on, because most companies treat shared command as a contradiction. Fulenwider and Molenaar treat it as the whole design. They met, recognized that each held half of what the company needed, and decided that two heads on one mission beat one head on two. Fulenwider carries the brand, the storytelling, the public voice; Molenaar carries the operating discipline that turns a good idea into a shipped prescription. Neither title is decorative. For a category that has been talked down to for decades, having two founders who refuse to simplify the message into a slogan turns out to be a feature, not a governance headache.

Her editing years explain the way Alloy speaks. Magazines taught her that information only helps people if they can actually find it, read it, and trust it - that the gap between a fact and a usable fact is mostly a writing problem. She has carried that into a corner of medicine notorious for shrugging. Menopause is not rare; roughly half the population will pass through it. Yet the science-backed options, the trained physicians, and the plain-language explanations have been scattered, gatekept, or simply absent. Alloy's pitch is unglamorous on purpose: gather the evidence, connect the patient to a doctor who actually specializes in this, and make the whole thing as easy to start as ordering anything else online. That is an editor's solution dressed as a healthcare product.

There is also a through-line of advocacy that predates the company. Across her media career she sat on advisory councils tied to women's leadership and public service, mentored emerging talent, and built editorial franchises whose entire purpose was visibility - putting women, and the people who shape culture for them, in front of an audience that might otherwise look elsewhere. Alloy is the same instinct with a different delivery mechanism. The cover line became a treatment plan. The reader became a patient. The point - that women in every stage of life deserve to be taken seriously - never changed.

The Forbes 50 Over 50 nod in 2024 landed as both recognition and argument. A list built to spotlight women who hit their stride after fifty is, conveniently, the demographic Alloy serves and the thesis Fulenwider has been making with her own biography. She did not peak as a young magazine prodigy and coast. She started over in her late forties, in an industry with a steep clinical learning curve, and built something measured in employees, capital raised, and patients reached. "Success and innovation have no age limit" is the kind of line that sounds like a poster until you notice the person saying it has receipts. She does.

What makes her unusual among founders is not the pivot itself - plenty of executives reinvent. It is that she brought the exact tool from her old life that her new field was missing. Healthcare did not need another former editor; it needed someone who understood that a confused, dismissed, under-informed audience is not a marketing problem to be spun but a story that has been told badly. Fulenwider has spent her whole career deciding what deserves the reader's attention. She decided this did. The rest is execution, and she is in the middle of it.